vs
卡博特（CBT）与GENMAB A/S（GMAB）财务数据对比。点击上方公司名可切换其他公司
GENMAB A/S的季度营收约是卡博特的1.1倍（$925.0M vs $849.0M），GENMAB A/S净利率更高（36.3% vs 8.6%，领先27.7%），GENMAB A/S同比增速更快（18.7% vs -11.1%），GENMAB A/S自由现金流更多（$327.0M vs $57.0M）
卡博特公司是总部位于美国马萨诸塞州波士顿的特种化学品和高性能材料企业，业务覆盖全球20多个国家，拥有36座生产工厂、8个研发中心及28个销售办事处，在特种材料领域具备全球领先的技术和服务能力。
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
CBT vs GMAB — 直观对比
营收规模更大
GMAB
是对方的1.1倍
$849.0M
营收增速更快
GMAB
高出29.8%
-11.1%
净利率更高
GMAB
高出27.7%
8.6%
自由现金流更多
GMAB
多$270.0M
$57.0M
损益表 — Q1 FY2026 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $849.0M | $925.0M |
| 净利润 | $73.0M | $336.0M |
| 毛利率 | 24.9% | 93.8% |
| 营业利润率 | 15.2% | 38.9% |
| 净利率 | 8.6% | 36.3% |
| 营收同比 | -11.1% | 18.7% |
| 净利润同比 | -21.5% | 65.5% |
| 每股收益（稀释后） | $1.37 | $5.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBTGMAB
| Q4 25 | $849.0M | — | ||
| Q3 25 | $899.0M | — | ||
| Q2 25 | $923.0M | $925.0M | ||
| Q1 25 | $936.0M | — | ||
| Q4 24 | $955.0M | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | $779.0M | ||
| Q1 24 | $1.0B | — |
净利润CBTGMAB
| Q4 25 | $73.0M | — | ||
| Q3 25 | $43.0M | — | ||
| Q2 25 | $101.0M | $336.0M | ||
| Q1 25 | $94.0M | — | ||
| Q4 24 | $93.0M | — | ||
| Q3 24 | $137.0M | — | ||
| Q2 24 | $109.0M | $203.0M | ||
| Q1 24 | $84.0M | — |
毛利率CBTGMAB
| Q4 25 | 24.9% | — | ||
| Q3 25 | 24.5% | — | ||
| Q2 25 | 26.4% | 93.8% | ||
| Q1 25 | 25.7% | — | ||
| Q4 24 | 24.6% | — | ||
| Q3 24 | 24.0% | — | ||
| Q2 24 | 25.2% | 96.4% | ||
| Q1 24 | 24.1% | — |
营业利润率CBTGMAB
| Q4 25 | 15.2% | — | ||
| Q3 25 | 15.2% | — | ||
| Q2 25 | 18.1% | 38.9% | ||
| Q1 25 | 17.3% | — | ||
| Q4 24 | 16.2% | — | ||
| Q3 24 | 15.0% | — | ||
| Q2 24 | 16.9% | 30.3% | ||
| Q1 24 | 15.3% | — |
净利率CBTGMAB
| Q4 25 | 8.6% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | 10.9% | 36.3% | ||
| Q1 25 | 10.0% | — | ||
| Q4 24 | 9.7% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 10.7% | 26.1% | ||
| Q1 24 | 8.2% | — |
每股收益（稀释后）CBTGMAB
| Q4 25 | $1.37 | — | ||
| Q3 25 | $0.80 | — | ||
| Q2 25 | $1.86 | $5.42 | ||
| Q1 25 | $1.69 | — | ||
| Q4 24 | $1.67 | — | ||
| Q3 24 | $2.41 | — | ||
| Q2 24 | $1.94 | $3.13 | ||
| Q1 24 | $1.49 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $230.0M | $1.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.6B | $5.3B |
| 总资产 | $3.8B | $6.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CBTGMAB
| Q4 25 | $230.0M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $239.0M | $1.3B | ||
| Q1 25 | $213.0M | — | ||
| Q4 24 | $183.0M | — | ||
| Q3 24 | $223.0M | — | ||
| Q2 24 | $197.0M | $622.0M | ||
| Q1 24 | $206.0M | — |
总债务CBTGMAB
| Q4 25 | — | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CBTGMAB
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.5B | $5.3B | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.3B | $4.4B | ||
| Q1 24 | $1.4B | — |
总资产CBTGMAB
| Q4 25 | $3.8B | — | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $3.8B | $6.5B | ||
| Q1 25 | $3.8B | — | ||
| Q4 24 | $3.6B | — | ||
| Q3 24 | $3.7B | — | ||
| Q2 24 | $3.6B | $5.6B | ||
| Q1 24 | $3.6B | — |
负债/权益比CBTGMAB
| Q4 25 | — | — | ||
| Q3 25 | 0.70× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.75× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.0M | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $57.0M | $327.0M |
| 自由现金流率自由现金流/营收 | 6.7% | 35.4% |
| 资本支出强度资本支出/营收 | 8.1% | 2.4% |
| 现金转化率经营现金流/净利润 | 1.73× | 1.04× |
| 过去12个月自由现金流最近4个季度 | $401.0M | — |
8季度趋势，按日历期对齐
经营现金流CBTGMAB
| Q4 25 | $126.0M | — | ||
| Q3 25 | $219.0M | — | ||
| Q2 25 | $249.0M | $349.0M | ||
| Q1 25 | $73.0M | — | ||
| Q4 24 | $124.0M | — | ||
| Q3 24 | $204.0M | — | ||
| Q2 24 | $207.0M | $438.0M | ||
| Q1 24 | $176.0M | — |
自由现金流CBTGMAB
| Q4 25 | $57.0M | — | ||
| Q3 25 | $155.0M | — | ||
| Q2 25 | $188.0M | $327.0M | ||
| Q1 25 | $1.0M | — | ||
| Q4 24 | $47.0M | — | ||
| Q3 24 | $112.0M | — | ||
| Q2 24 | $155.0M | $430.0M | ||
| Q1 24 | $133.0M | — |
自由现金流率CBTGMAB
| Q4 25 | 6.7% | — | ||
| Q3 25 | 17.2% | — | ||
| Q2 25 | 20.4% | 35.4% | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 4.9% | — | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | 15.3% | 55.2% | ||
| Q1 24 | 13.1% | — |
资本支出强度CBTGMAB
| Q4 25 | 8.1% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 6.6% | 2.4% | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 8.1% | — | ||
| Q3 24 | 9.2% | — | ||
| Q2 24 | 5.1% | 1.0% | ||
| Q1 24 | 4.2% | — |
现金转化率CBTGMAB
| Q4 25 | 1.73× | — | ||
| Q3 25 | 5.09× | — | ||
| Q2 25 | 2.47× | 1.04× | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | 1.49× | — | ||
| Q2 24 | 1.90× | 2.16× | ||
| Q1 24 | 2.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBT
| Reinforcement Materials | $520.0M | 61% |
| Performance Chemicals | $300.0M | 35% |
| Shipping And Handling | $25.0M | 3% |
| Other Products And Services | $4.0M | 0% |
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
